在帕金森病中,非麻烦性运动障碍的患病率
Hee Jin Chang1, Mihee Jang2, Kyung Ah Woo3
1Department of Neurology, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
Parkinsonism & related disorders
|April 7, 2024
概括
在帕金森病 (PD) 中,Levodopa诱导的运动障碍是常见的,但即使经过几十年的治疗,也往往不会造成麻烦. 这项研究强调,许多PD患者长期经历非致残性运动障碍.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 帕金森病研究 帕金森病研究
背景情况:
- 莱沃多巴诱导的动力障碍是长期帕金森病 (PD) 管理中的常见并发症.
- 功能障碍对患者日常功能的影响仍然是争论的主题.
- 了解非麻烦性运动障碍对于有效的PD长期护理至关重要.
研究的目的:
- 为了确定帕金森病患者肌动力障碍的患病率和严重程度.
- 专门调查非麻烦性运动障碍的发生情况.
- 为长期帕金森病管理策略提供信息.
主要方法:
- 对2571名帕金森病患者电子病历的回顾性审查.
- 从2016年1月至2017年6月期间在首尔国立大学医院看到的患者收集的数据.
- 功能障碍症的严重程度使用功能影响量表 (0-4) 进行评估,较高的分数表明更大的残疾.
主要成果:
- 功能障碍的患病率随着帕金森病持续时间的延长而增加,在21年以上后达到83.2%.
- 显著动力障碍的患病率 (得分≥2) 也随着疾病持续时间的增加而增加,在21年或以上的患者中,影响73.7%.
- 大约有26.3%的患者经历了不麻烦的动力障碍,即使经历了21年多的PD.
结论:
- 随着帕金森病持续时间的延长,肌动力障碍的患病率和严重程度会升级.
- 很大一部分患者经历了非麻烦的动力障碍,即使在PD的晚期阶段.
- 这些发现表明,对于许多长期患有帕金森病的患者来说,功能障碍可能不会显著影响日常功能.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
312
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
312


